600294.png
[Hide] (9.2MB, 4500x3500) >>25306
>wow proof?
I mean this reply is pretty good proof of the kind of disingenuous bullshit and total lack of interest in scholarship or other's-and-your-own wellbeing that you're constantly putting out.
With regards to the shrooms, there's a fair number of studies for how hard it is to get permission to do them, but you'd have to give discreet cases to get specific examples.
Addiction and depression are two of the most widely established, the former of which I think it's reasonable to say might be an issue for wish and the latter of which he's literally on medication for.
>wow proof?
Literal top results:
"psilocybin addiction"
>Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.
>Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
>Matthew W Johnson, Albert Garcia-Romeu1, Mary P Cosimano and Roland R Griffiths (2014)
"psilocybin depression"
>Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS diff erence –11·8, 95% CI –9·15 to –14·35, p=0·002, Hedges’ g=3·1) and 3 months (–9·2, 95% CI –5·69 to –12·71, p=0·003, Hedges’ g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.
>Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
>Robin L Carhart-Harris, Mark Bolstridge, James Rucker*, Camilla M J Day*, David Erritzoe, Mendel Kaelen, Michael Bloomfi eld, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nutt (2016)
And of course, there's a tremendous number of self-reports of this efficacy, to the extent that in tandem with the scientific support I would say it's reasonable to claim that it's common knowledge that psychs (the formal literature for LSD is more substantial than for shrooms, especially for addiction) help with depression and that psychs help with addiction. As someone who unwelcomely hangs around a board with raver cultural influences essentially a favela atmosphere, there's no way you haven't seen dozens of these accounts.
Kill yourself faggot